Rheumatoid arthritis (RA) remains a prevalent, progressive autoimmune disease leading to synovial inflammation, joint erosion, and systemic morbidity. Recent advances in diagnosis emphasize earlier and more accurate detection through high-sensitivity imaging (musculoskeletal ultrasound, MRI), improved serological assays (anti-cyclic citrullinated peptide, refined rheumatoid factor testing), and composite risk models that integrate clinical, imaging, and biomarker data to identify preclinical or early disease. Therapeutically, the paradigm has shifted to treat-to-target strategies aiming for sustained remission or low disease activity, supported by a growing armamentarium of targeted therapies. Biologic disease-modifying antirheumatic drugs that inhibit tumor necrosis factor and interleukin-6 pathways transformed outcomes, while small-molecule Janus kinase inhibitors provide effective oral alternatives with distinct mechanisms. Precision medicine approaches leveraging genomic, epigenetic, and microbiome signatures are under development to predict drug response and tailor therapy. Digital health tools, telemedicine, and patient-reported outcome measures facilitate tight disease control and shared decision-making. Moreover, artificial intelligence and machine learning are being applied to imaging interpretation and predictive modeling to enhance diagnostic accuracy and forecast therapeutic response. Safety advances include standardized monitoring frameworks that mitigate infection and cardiovascular risks associated with immunomodulation. Despite therapeutic progress, challenges persist: treatment access and cost, long-term safety surveillance, and the need for validated predictive biomarkers to guide individualized care. Ongoing interdisciplinary research, implementation of equitable care models, and integration of emerging diagnostics and therapeutics into clinical pathways promise to further improve functional outcomes and quality of life for people living with RA and reduce long-term disability while promoting equitable, cost-effective care globally sustainably.